Année :

4P-Pharma et Oncocross signe un accord de collaboration de recherche

4P-Pharma and Oncocross, a Korea-based AI biotech,  signed a research collaboration agreement at the Institut Pasteur de Lille on October 25th, 2021. The two companies will join their expertise to bring an innovative therapeutic agent to the patients affected by Systemic Scleroderma, a rare autoimmune disease affecting the skin and internal organs that has no approved treatment in&hellip

Lire la suite